Citations

Clear

16 citation(s) found for "Stelzig, Kimberly".

C27-10 EphA2 Receptor Tyrosine Kinase Regulates Alveolar Macrophage Inflammatory Responses During Pneumocystis Pneumonia
Limper, A H, Kottom, T J, Pellegrino, M R, Stelzig, K E, Achilonu, C C, Limper, Andrew H. , Kottom, Theodore J. , Pellegrino, Madeline R., Stelzig, Kimberly E. , Achilonu, Conrad Chibunna

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4413 Get It

Abstract Alveolar macrophages (AMs) are critical for host defense and immunity against Pneumocystis. Through surface-associated receptors, AMs recognize, phagocytose, and kill Pneumocystis organisms, producing cytokines that promote pathogen clearance but also contribute to lung inflammation and injury. The EphA2 receptor, a member of the receptor tyrosine kinase (RTK) family, contains an extracellular region that binds activating ligands (Ephrins) and, more recently, has been shown to bind fungal β-glucans, leading to activation of its intracellular tyrosine kinase domain. The EphA2 signaling pathway has important roles in cancer, angiogenesis, and inflammatory diseases such as atherosclerosis. EphA2 is highly expressed in epithelial and endothelial cells, and emerging evidence indicates that it serves as a critical regulator of host defense against bacterial, viral, and fungal pathogens. In oropharyngeal candidiasis, EphA2 was identified as a receptor for fungal β-glucans in oral epithelial cells, mediating proinflammatory signaling through signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK) pathways. Our laboratory recently demonstrated that EphA2 on lung epithelial cells binds Pneumocystis organisms, and that β-glucans from these organisms activate downstream signaling leading to IL-6 release. However, the role of EphA2 signaling in AM immune responses during Pneumocystis pneumonia (PCP) remains unknown. To address this, we examined EphA2-deficient (EphA2−/−) AMs stimulated with Pneumocystis β-glucans. Compared to wild-type AMs, EphA2−/− AMs exhibited significantly decreased production of proinflammatory cytokines, including IL-6 and TNF-α. In CD4-depleted mouse models of PCP, EphA2−/− lungs displayed markedly reduced levels of inflammatory cytokines and increased organism burdens, indicating impaired immune activation but preserved fungal persistence. Importantly, in CD4-depleted mice undergoing standard trimethoprim-sulfamethoxazole (TMP/SMX) therapy, concurrent administration of the EphA2 small-molecule inhibitor ALW-II-41-27 significantly reduced lung TNF-α responses without evidence of toxicity. These findings demonstrate that EphA2 receptor signaling plays a critical role in regulating macrophage-mediated inflammatory responses to Pneumocystis. While EphA2 deficiency dampens pulmonary inflammation, it also compromises fungal clearance, highlighting a delicate balance between host defense and immunopathology. Our data suggest that targeted modulation of EphA2 signaling during anti-Pneumocystis therapy may provide a novel adjunctive approach to reduce detrimental lung inflammation associated with PCP, potentially improving outcomes in affected patients. This abstract is funded by: NIH R01 HL-62150
C27-09 Targeting Phosphoglucomutase (PGM) as a Novel Antifungal Strategy in Pneumocystis: Functional and Therapeutic Evidence Supporting a Conserved Cysteine Target
Limper, A H, Kottom, T J, Pellegrino, M R, Achilonu, C C, Stelzig, K E, Limper, Andrew H. , Kottom, Theodore J. , Pellegrino, Madeline R., Achilonu, Conrad Chibunna , Stelzig, Kimberly E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4412 Get It

Abstract Rationale Pneumocystis pneumonia (PJP) remains a major opportunistic infection in immunocompromised hosts, with limited therapeutic options. Previous studies identified a conserved cysteine residue (C353) in Pneumocystisphosphoglucomutase (PGM), analogous to that found in other pathogenic fungi but absent in mammalian PGMs, suggesting an exploitable antifungal target. We aimed to define the functional significance and therapeutic potential of targeting Pneumocystis PGM. Methods Full-length P. jirovecii and P. murina PGM cDNAs were cloned into S. cerevisiae pgm2Δ yeast (deficient in PGM activity) using the pYES2.1 TOPO vector for heterologous expression. Recombinant yeast lysates were tested for PGM activity in the presence of the thiol-reactive inhibitor ISFP10 (0-200 μM). Parallel assays were performed using recombinant human PGM lacking C353. Yeast growth inhibition in these strains in the presence of ISFP10 was also measured over 72 hours. For in vitro and ex vivo assays, P. murina organisms were treated with ISFP10, and viability was quantified via qPCR of the mitochondrial 16S ribosomal copy number. Precision-cut lung slice (PCLS) ex vivo cultures from a murine PCP model and in vivo CD4-depleted mice were used to assess ISFP10 efficacy and toxicity. Results Both P. jirovecii and P. murina PGMs showed potent, dose-dependent inhibition of enzymatic activity by ISFP10 up to 12.5 μM, with no inhibition of human PGM at concentrations up to 200 μM. Yeast complementation assays confirmed that ISFP10 significantly reduced the growth of pgm2Δ yeast expressing Pneumocystis spp. PGM. In vitro incubation of P. murina with ISFP10 resulted in significant reductions in organismal 16S mitochondrial copy number, comparable to pentamidine. In ex vivo PCLS models, ISFP10 decreased P. murina burden without affecting uninfected tissue viability. In vivo, ISFP10 administration for seven days significantly reduced fungal burden in CD4-depleted mice with an acceptable safety profile. Conclusions These findings demonstrate that Pneumocystis PGM activity depends on a conserved cysteine residue that is selectively targetable by ISFP10. Pharmacologic inhibition of PGM impairs P. murina viability in vitro, ex vivo, and in vivo with minimal host toxicity. Collectively, these data establish PGM as a promising, fungus-specific antifungal target and support the further development of small-molecule inhibitors targeting Pneumocystis PGM. This abstract is funded by: NIH R01 HL-62150, R21 AI-181542
The Tyrosine Kinase Receptor EphA2 in Alveolar Macrophages Provides a Protective Role in Host Defense Against Pneumocystis Pneumonia
Kottom, Theodore J. , Pellegrino, Madeline, Achilonu, Conrad Chibunna , Stelzig, Kimberly E. , Limper, Andrew H. , Stelzig, Kimberly E. , Achilonu, Conrad C , Limper, Andrew H , Kottom, Theodore J , Pellegrino, Madeline R.

Mayo Clinic

The Journal of Infectious Diseases | April 21, 2026 | Volume: 234 | Issue: 1 | Pages: 154-163

10.1093/infdis/jiag228 | PMID 42028745 Get It

Abstract Background Alveolar macrophages (AMs) are central to host defense against Pneumocystis, mediating organism clearance while also contributing to lung inflammation. EphA2, a transmembrane receptor that binds fungal β-glucans, has emerged as a regulator of host–pathogen interactions, but its role in AM responses during Pneumocystis pneumonia (PCP) is unknown. Methods We evaluated AM inflammatory responses to Pneumocystis β-glucans in the presence and absence of EphA2. In vivo studies used a CD4-depleted mouse model of PCP comparing wild-type and EphA2-deficient (EphA2−/−) mice. Lung cytokine responses and organism burden were assessed. Additionally, EphA2 signaling was pharmacologically inhibited using ALW-II-41-27 during trimethoprim-sulfamethoxazole treatment. Results EphA2 deficiency significantly reduced AM proinflammatory cytokine responses to Pneumocystis β-glucans. In CD4-depleted PCP mice, EphA2−/− animals demonstrated decreased lung inflammatory cytokines, but increased organism burden compared to controls. Pharmacologic inhibition of EphA2 during antimicrobial therapy significantly suppressed lung inflammation. Conclusions EphA2 signaling plays a critical role in AM-mediated host defense against Pneumocystis by promoting inflammatory responses necessary for organism control. However, this pathway also contributes to lung inflammation. Targeting EphA2 may represent a novel strategy to modulate inflammation during severe PCP while preserving antimicrobial defense.
The importance of Fcγ and C-type lectin receptors in host immune responses during Pneumocystis pneumonia
Carmona, Eva M. , Schaefbauer, Kyle, Stelzig, Kimberly E. , Pellegrino, Madeline R., Bindzus, Marc, Limper, Andrew H. , Kottom, Theodore J. , Limper, Andrew H , Carmona, Eva M

Mayo Clinic

Infection and Immunity | December 31, 2024 | Volume: 93 | Issue: 2 | Pages: No page available

10.1128/iai.00276-24 | PMID 39745390 Get It

ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a significant cause of morbidity and mortality during AIDS. In AIDS, the absence of CD4 immunity results in exuberant and often fatal PJP. In addition, organism clearance requires a balanced macrophage response since excessive inflammation promotes lung injury and respiratory failure. Corticosteroids given in addition to antibiotics significantly improve outcomes during PJP. However, concerns exist that corticosteroids further suppress immunity and increase co-infections. New strategies to promote killing and clearance of Pneumocystis while balancing lung inflammation are required. Prior studies have shown that innate immunity to Pneumocystis is mediated by C-type lectin receptors (CLRs) on macrophages and involves downstream CARD9 activation. CARD9 can be targeted by a novel specific small molecule inhibitor (BRD5529) that significantly reduces inflammatory signaling by macrophages. CARD9 serves as the central intracellular molecule through which Dectin-1, Dectin-2, Mincle, and other CLRs signal. Dectin-1 CLR is activated through its own intracytoplasmic domain, whereas other innate CLRs (e.g., Dectin-2 and Mincle) require interactions with a common Fc-gamma receptor (FcγR) accessory chain to mediate responses. We now observe that mice double deficient in both Dectin-1 and Fcer1g (which lack the FcγR gamma chain) exhibit markedly reduced organism clearance compared with Card9 −/− infected animals. These mice also possess deficiencies in immunoglobulin (Ig) Fc receptors directly mediating antibody responses, further implicating altered humoral responses in Pneumocystis killing. We further demonstrate in the Pneumocystis pneumonia (PCP) mouse model that BRD5529 administration successfully suppresses inflammatory cytokines. Our data support that innate immune responses through the CLR-CARD9 axis and humoral response act together to mediate effective responses resulting in optimal organism killing and generation of host inflammatory responses. Furthermore, host lung inflammation during PCP may be successfully reduced with a novel CARD9 small molecule inhibitor. IMPORTANCE Pneumocystis pneumonia (PCP) causes severe respiratory impairment in hosts with suppressed immunity, particularly those with CD4 deficiencies, such as HIV. In addition to lymphocytic immunity, both innate and humoral immunities also participate in host defense against Pneumocystis . In the current studies, we defined the relative roles of CLR receptor-mediated inflammation, as well as FcgR-related inflammation and clearance of Pneumocystis organisms. Our studies reveal important roles for CLR activities for inducing lung inflammation, which can be ameliorated with a novel small molecule inhibitor of the CARD9 adaptor protein that is necessary for CLR signaling. In contrast, FcgR has a dominant role in organism clearance, underscoring an integral role of humoral responses for the elimination of this infection.
Tmem178 Regulates Calcium Responses in Normal Human Bronchial Epithelial Cells
Botero, A.M. Hernandez, Stelzig, Kimberly E. , Botero, A.M. Hernandez, Pabelick, Christina M. , Prakash, Y. S. , Chiarella, Sergio E.

Mayo Clinic

A31. GLOBAL AND ENVIRONMENTAL INFLUENCES IN ASTHMA | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1304-A1304

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1304 Get It

TMEM178 Inhibits Allergic Lung Inflammation in a Murine Model of Asthma
Stelzig, Kimberly E. , Botero, A.M. Hernandez, Botero, A.M. Hernandez, Pabelick, Christina M. , Prakash, Y. S. , Chiarella, Sergio E.

Mayo Clinic

A31. GLOBAL AND ENVIRONMENTAL INFLUENCES IN ASTHMA | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1297-A1297

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1297 Get It

Genomic evidence for dysregulated glutamine metabolism in the asthmatic airway epithelium
Bravo‐Solarte, Daniela C. , Stelzig, Kimberly E. , Cuervo‐Pardo, Lyda , Berdnikovs, Sergejs , Chiarella, Sergio E , Stelzig, Kimberly E. , Chiarella, Sergio E.

Mayo Clinic

Clinical and Translational Allergy | July 5, 2022 | Volume: 12 | Issue: 7 | Pages: No page available

10.1002/clt2.12178 | PMID 35813976 Get It

Sex Differences in Whole Lung B Cell Subsets in a Murine Model of Asthma
Drake, L.Y., Stelzig, K., Bravo-Solarte, D., Chiarella, S.E., Stelzig, Kimberly E. , Pabelick, Christina M. , Prakash, Y. S. , Chiarella, S E

Mayo Clinic

A32. UPDATES IN THE MOLECULAR AND CELLULAR UNDERPINNINGS OF ASTHMA | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1272-A1272

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1272 Get It

Passive siRNA transfection method for gene knockdown in air-liquid interface airway epithelial cell cultures
Bartman, Colleen M. , Stelzig, Kimberly E. , Prakash, Y. S. , Prakash, Y S , Chiarella, Sergio E , Stelzig, Kimberly E. , Bartman, Colleen M , Linden, David R. , Chiarella, Sergio E.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | May 26, 2021 | Volume: 321 | Issue: 1 | Pages: L280-L286

10.1152/ajplung.00122.2021 | PMID 34037474 Get It

Differentiation of human bronchial epithelial cells (HBEs) in air-liquid interface (ALI) cultures recapitulates organotypic modeling of the in vivo environment. Although ALI cultures are invaluable for studying the respiratory epithelial barrier, loss-of-function studies are limited by potentially cytotoxic reagents in classical transfection methods, the length of the differentiation protocol, and the number of primary epithelial cell passages. Here, we present the efficacy and use of a simple method for small interfering RNA (siRNA) transfection of normal HBEs (NHBEs) in ALI cultures that does not require potentially cytotoxic transfection reagents and does not detrimentally alter the physiology or morphology of NHBEs during the differentiation process. This transfection protocol introduces a reproducible and efficient method for loss-of-function studies in HBE ALI cultures that can be leveraged for modeling the respiratory system and airway diseases.
Brain Derived Neurotrophic Factor and Airway Hyperreactivity in a Mouse Model of Allergic Asthma in Aging
Wicher, S.A., Roos, B., Nesbitt, Lisa, Stelzig, Kimberly E. , Drake, Li Y. , Fang, Yun Hua , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

TP118. TP118 AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A4501-A4501

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4501 Get It